Past studies have shown that women are less likely to be treated with statin therapy,49, 50 and as APOE ε4 carriers have increased risk for dyslipidemia; this likely increases the likelihood of patients with this genotype to be treated with statins.53 Here, APOE is linked to metabolic syndrome.